Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N, Wan G, Ugwu-Dike P, Alexander NA, Raval N, Zhang S, Jairath R, Phillipps J, Leung B, Roster K, Seo J, Lu C, Tang K, Choi MS, DeSimone MS, Theodosakis N, Amadife M, Cox N, Le TK, Liu F, Chen W, Bai X, Boland G, Liu D, Hurlbert MS, LeBoeuf N, Reynolds KL, Yu KH, Tsao H, Asgari M, Gusev A, Kwatra SG, Semenov YR. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy. J Am Acad Dermatol. 2023 06; 88(6):1308-1316.